Installation of a new AST GENiSYS C automated vial, syringe and cartridge line will take place during the course of the next year.
The new line will operate under state-of-the-art full isolator conditions and is ideally suited for clinical and small-scale commercial supply for high-value substances.
“Bora is more frequently seeing demand for drug product fill and finish of potent drug candidates and approved treatments, as well as for rare and orphan diseases,” commented J.D. Mowery, President of Bora’s CDMO Division.
“The addition of a precision small-scale isolator line adds to our overall capacity, and working in concert with our existing large-scale lines, increases our flexibility and scalability. I look forward to adding to our capabilities in the U.S. so that we remain ready to meet rising demand from clients, both domestic and international.”
Bora’s 87,000 sq. ft. Baltimore facility provides drug product manufacturing services for sterile injectables and offers clinical and commercial non-viral aseptic fill/finish services for vials and prefilled syringes on four fill lines, in addition to lyophilisation, terminal sterilisation, analytical, stability, packaging and serialisation and additional support services.